A chromatin target for ALL

An NYU School of Medicine–GSK collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia and might avoid the safety pitfalls of other notch 1–targeted therapies.